InnoCare Pharma Ltd reported a 55.5% year-over-year increase in total revenue to RMB 1.137 billion for the first half of 2026, driven by an 80.7% rise in drug sales to RMB 918 million. The company swung to a net profit of RMB 240 million, compared with a loss of RMB 36 million in the same period of 2025, and posted diluted earnings per share of RMB 0.14.
Cash and cash equivalents stood at approximately RMB 8.4 billion as of June 30, 2026, while operating cash flow was positive during the period. Research and development expenditure rose 10.5% year-over-year to RMB 497 million.
Shares of InnoCare fell 6.96% to $27.54 following the results, extending declines from a prior close of $29.60. The stock has traded between $12.14 and $33.33 over the past 52 weeks.
Management maintained full-year 2026 drug sales growth guidance above 35% and reiterated expectations for full-year profitability, with EPS expected to exceed the first-half level of RMB 0.14. The company employs around 500 sales professionals across more than 1,500 hospitals in China and is conducting over 10 phase III registrational studies globally.
InnoCare’s pipeline includes orelabrutinib, tafasitamab, zurletrectinib, and multiple antibody-drug conjugates such as ICP-B794, ICP-B208, and ICP-B381. The company also highlighted mesutoclax, a BCL2 inhibitor, which demonstrated higher exposure than venetoclax at standard dosing. Clinical data showed a 100% overall response rate and 57% complete response rate in frontline chronic lymphocytic leukemia/small lymphocytic lymphoma when combined with orelabrutinib.
Additional pipeline programs include soficitinib and fadeucravacitinib, both TYK2/JAK1 inhibitors, as well as ICP-054 and ICP-538, currently in Phase I development. The company submitted a China investigational new drug application for ICP-B381 in August 2026 and expects to file in the U.S. in September 2026.
CFO Xin Fu noted that the company delivered "a very strong financial performance" in H1 2026, while CEO Jasmine emphasized the company’s strong cash position and disciplined approach to partnerships. Yuan Ding, head of hematology oncology, described mesutoclax as having "enormous market potential" across lymphoma and leukemia indications.
